This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Navidea Biopharmaceuticals Provides Financing Update

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has closed on an initial draw of $2 million under its line of credit with Platinum-Montaur Life Sciences, LLC (Montaur).

On July 26, 2012, the Company announced the availability of up to $50 million under the debt facility with Montaur. This $2 million draw is part of an initial $15 million Navidea can draw on at any time as the first part of the overall line. Montaur has committed to provide an additional $20 million upon approval of Lymphoseek ®, with yet an additional $15 million potentially available on terms to be negotiated. Interest on the draws made under the facility is based on the prime rate and is currently set at approximately 10 percent per annum. Principal under the facility is generally repayable two years from the date a draw is funded, subject to certain conditions. No conversion features or warrants are associated with the facility.

“We are pleased to have now accessed the debt facility put in place with Montaur some time ago. In addition, Montaur has indicated it intends to exercise certain warrants set to expire soon that are related to past transactions, which we anticipate will provide another $1.9 million in proceeds to the Company before year-end. We believe the completed drawdown, coupled with the proceeds from the anticipated warrant exercise, exemplify Montaur’s continued support for the Company as well as the strength and flexibility of our financial model,” said Brent Larson, Navidea Senior Vice President and CFO. “The Company has access to substantial financial resources that provide us with important financial flexibility. We intend to access funding as needed to maintain a strong balance sheet to support the significant progress in our development programs and prepare for Lymphoseek commercialization, as we confidently anticipate US approval.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,673.89 -4.34 -0.02%
S&P 500 2,058.18 +2.03 0.10%
NASDAQ 4,873.96 +10.5980 0.22%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs